资讯

Ionis Pharmaceuticals (IONS) Is Up 43.6% After Positive Phase 3 Olezarsen Results in Severe ...

Ionis Pharmaceuticals announced positive topline results from its pivotal Phase 3 CORE and CORE2 studies of olezarsen in severe hypertriglyceridemia, with highly statistically significant reductions ...